Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W. Insull Jr.
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review.
Southern Med J, 99 (2006), pp. 257-273
[2.]
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
JAMA, 251 (1984), pp. 351-364
[3.]
H.E. Bays, R.B. Goldberg.
The “forgotten” bile acid sequestrants: is now a good time to remember?.
Am J Ther, 14 (2007), pp. 567-580
[4.]
M.H. Davidson.
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia.
J Clin Lipidol, 5 (2011), pp. 76-81
[5.]
E. Ros.
Eficacia, seguridad e indicaciones de la colestiramina en el tratamiento de la hipercolesterolemia.
Rev Clin Esp, 206 (2006), pp. 27-30
[6.]
B. Staels.
A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus.
Postgrad Med, 121 (2009), pp. 25-30
[7.]
G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, et al.
Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.
Lancet, 378 (2011), pp. 31-40
[8.]
B. Staels, Y. Handelsman, V. Fonseca.
Bile acid sequestrants for lipid and glucose control.
Curr Diab Rep, 10 (2010), pp. 70-77
[9.]
M. Studer, M. Briel, B. Leimenstoll, T.R. Glass, H.C. Bucher.
Effect of different antilipemic agents and diets on mortality. A systematic review.
Arch Int Med, 165 (2005), pp. 725-730
Copyright © 2011. Sociedad Española de Arteriosclerosis y Elsevier España S.L.